Signal from the log
Cloverleaf Bio
33 M$ · Seed · United States · Biotech
Essaimage de Yale installé à New Haven, dans le Connecticut, qui conçoit des ARN de transfert modifiés comme charge active contre le cancer. Deux programmes, un carcinome hépatocellulaire et un conjugué anticorps-ARNt en cancer colorectal. Le Form D déposé le 9 septembre déclare 14,8 M$ effectivement placés au 24 août, sur 29,6 M$ autorisés.
Verified
Announced on , logged by the watch of 9 September 2026.
- Operation
- Funding round
- Announced amount
- 33 M$
- Stage
- Seed
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by 4BIO Capital , with AbbVie Ventures , Eli Lilly and Company , Boehringer Ingelheim Venture Fund , Draper Associates , Mission BioCapital , American Cancer Society BrightEdge
Provenance
Source edgar,pulse2
Logged on 9 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.